Targeting 4-1BB for tumor immunotherapy from bench to bedside: Immune dysfunction has been proposed as a factor that may contribute to disease progression. Emerging evidence suggests that immunotherapy aims to abolish cancer… #immunology https://t.co/vyEE7
17,283 followers
1,460 followers
RT @FrontImmunol: New Research: Targeting 4-1BB for tumor immunotherapy from bench to bedside: Immune dysfunction has been proposed as a fa…
32,811 followers
New Research: Targeting 4-1BB for tumor immunotherapy from bench to bedside: Immune dysfunction has been proposed as a factor that may contribute to disease progression. Emerging evidence suggests that immunotherapy aims to abolish cancer… https://t.co/o2u